Chemokines and chemokine receptors in HIV infection: Role in pathogenesis and therapeutics

Journal of Postgraduate Medicine

Volumn 52, Issue 3, 2006, Pages 210-217

  Suresh, P ^a   Wanchu, A ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Anti HIV therapy; Chemokine; HIV 1; Host factors; Pathogenesis

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA CHEMOKINE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 070; AMINOOXYPENTANE; BETA CHEMOKINE; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COMPOUND 167; E 913; GLYCOPROTEIN GP 120; KRH 1636; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICROBICIDE; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PIPERAZINEDIONE; PRO 140; RANTES; SHC C; SHC D; STROMAL CELL DERIVED FACTOR 1; T 22; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUCOSAL IMMUNITY; PROMOTER REGION; REVIEW; SYSTEMATIC REVIEW; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VIRUS RESISTANCE;

CHEMOKINES; DRUG DESIGN; HIV; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4;

EID: 33746610538     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Walker CM, Moody DJ, Stites DP, Levy JA. CD8 + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
2. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T Cells. Immunol Today 1996;17:217-24.
3. Cocchi F, de Vico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP- 1 alpha and MIP-1 beta as the major HIV suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease. Annu Rev Immunol 1999;17:657-700.
5. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
6. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
7. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
8. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC-CKR5: A RANTES, MIP- 1 alpha, MIP- 1 beta receptor as fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8.
9. Choe H, Farzan M, Sun Y, Sullivan Y, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48.
10. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996;85:1149-58.
11. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 envelope glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-53.
12. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: Fusogen, antigens and immunogens. Science 1998;280:1884-8.
13. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5. Nature 1996;384:179-83.
14. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature 1998;391:240.
15. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as co-receptors for virus entry. J Virol 1996;70:8355-60.
16. Deng HK, Unutmaz D, Kewal Ramani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997;388:296-300.
17. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL-33, a novel chemokine receptor-like protein, functions as fusion cofactor for both macrophage-tropic and T cell tropic HIV-1. J Exp Med 1997;185:2015-23.
18. Louisirirotchanakul S, Liu H, Roongpisuthlpong A, Nakayama EE, Takebe Y, Shioda T, et al. Genetic analysis of HIV-1 discordant couples in Thailand: Association of CCR2 64I homozygosity with HIV-1 negative status. J Acquir Immune Defic Syndr 2002;29:314-5.
19. Neil SJ, Aasa-Chapman MM, Clapham PR, Nibbs RJ, McKnight A, Weiss RA. The promiscuous CC chemokine receptor D6 is a functional co-receptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J Virol 2005;79:9618-24.
20. Luster AD. Chemokines- chemotactic cytokines that mediate inflammation. N Eng J Med 1998;338:436-45.
21. Hernanz-Falcon P, Rodriguez-Frade JM, Serrano A, Juan D, delSol A, Soriano SF, et al. Identification of amino acid residues crucial for chemokine receptor dimerization. Nat Immunol 2004;5:216-23.
22. Rodriguez-Frade JM, del Real G, Serrano A, Hernanz-Falcon P, Soriano SF, Vila-Coro AJ, et al. Blocking of HIV infection via CCR5 and CXCR-4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J 2004;23:66-76.
23. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez-AC, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 1999;13:1699-71.
24. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Still A, Blattner WA, et al. Spontaneous and antigen induced production of HIV inhibitory b-chemokines are associated with AIDS free status. Proc Natl Acad Sci USA 1999;96:11986-91.
25. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998;177:331-6.
26. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Qulillent C, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4+ T cells from exposed uninfected individuals expressing the wild-type CCR5 allele. J Exp Med 1997;186:455-60.
27. Shieh B, Yan YP, Ko NY, Liau YE, Liu YC, Lin HH, et al. Detection of elevated serum beta-chemokine levels in seronegative Chinese individuals exposed to human immunodeficiency virus type 1. Clin Infect Dis 2001;33:273-9.
28. Skurnick JH, Palumbo P, de Vico A, Shacklett BL, Valentine FT, Merges M, et al. Correlates of non transmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002;185:428-38.
29. Saha K, Bentsman G, Chess L, Volsky DJ. Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type-1 (HIV-1) individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 1998;72:876-81.
30. Cocchi F, de Vico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, et al. Higher macrophage inflammatory protein (MIP) 1-alpha and MIP1-beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000;97:13812-7.
31. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997;3:1250-7.
32. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed uninfected individuals: Association with low expression of CCR5 and high production of beta-chemokines. Virology 1998;244:66-73.
33. Fowke KR, Dong T, Rowland-Jones SL, Oyugi J, Rutherford WJ, Kimani J, et al. HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced beta-chemokine production. AIDS Res Hum Retroviruses 1998;14:1521-30.
34. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, et al. HIV specific cytotoxic T lymphocytes, HLA A11 and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta 32 negative female sex workers in Chiang Rai, Northern Thailand. AIDS Res Hum Retrov 2001;17:719-34.
35. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999;96:4581-5.
36. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1 seronegative African women. J Infect Dis 2001;184:1412-22.
37. Butera ST, Pisell TL, Limpakarnjanarat K, Young NL, Hodge TW, Mastro TD, et al. Production of a novel viral suppressive activity associated with resistance to infection among female sex workers exposed to HIV type 1. AIDS Res Hum Retroviruses 2001;17:735-44.
38. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication [Letter]. Nature 1996;382:767.
39. Schmidtmayerova H, Nottet HS, Nuovo G, Raabe T, Flanagan CR, Dubrovsky L, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph node. Proc Natl Acad Sci USA 1996;93:700-4.
40. Canque B, Rosenzwajg M, Gey A, Tartour E, Fridman WH, Gluckman JC, et al. Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood 1996;87:2011-9.
41. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM. The C-X-C chemokine IP-10 stimulate HIV-1 replication. Virology 2003;307:122-34.
42. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998;187:601-8.
43. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998;95:3117-21.
44. Narimatsu R, Wolday D, Patterson BK. IL-8 increases transmission of HIV type 1 in cervical explant tissue. AIDS Res Hum Retroviruses 2005;21:228-33.
45. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA, et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 2003;9:191-7.
46. Reinhart TA. Chemokine induction by HIV-1: Recruitment to the cause. Trends Immunol 2003;24:351-3.
47. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
48. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City cohort, ALIVE Study. Science 1996;273:1856-62.
49. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-3.
50. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role of mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3.
51. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Comdadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background and quantified risk. Mol Med 1997;3:23-36.
52. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, et al. Homozygous delta 32 deletion of the CCR5 chemokine receptor gene in an HIV-1 infected patient. AIDS 1997;11:F67-71.
53. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group [Letter]. Lancet 1997;349:1219-20.
54. Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, Purcell DF, et al. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol. 2006;80:3684-91.
55. Gorry PR, Zhang C, Wu S, Kunstman K, Trachtenberg E, Phair J, et al. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 2002;359;1832-4.
56. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from person who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996;2:412-7.
57. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City cohort (SFCC), ALIVE Study. Science 1997;277:959-65.
58. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282:1907-11.
59. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Brorsen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-90.
60. Meyer L, Magierowska M, Hubert JB, Theodorou I, van Rij R, Prins M, et al. CC-chemokine receptor variants, SDF-1 polymorphism and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS [Letter]. AIDS 1999;13:624-6.
61. Ioannidis JP, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ. Genetic effects on HIV disease progression [Letter]. Nat Med 1998;4:536.
62. Carrington M, Kissner T, Gerrard B, Ivanov S, O'brien SJ, Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997;61:1261-7.
63. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Metais P, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998;351:14-8.
64. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′-end heterogeneity, dual promoter usage and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997;272:30662-71.
65. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Muticenter AIDS Cohort Study (MACS). Lancet 1998;352:866-70.
66. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, et al. Genealogy of the CCR5 locus and the chemokine system gene variants associated with altered rates of HIV-1 progression. Nat Med 1998;4:786-93.
67. Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type-1 to African-American infants. J Virol 1999;73:10264-71.
68. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4:350-3.
69. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, Rowland-Jones SL. CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet 1998;351:1632-3.
70. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: The protection varies with duration of infection. AIDS 2003;17:377-87.
71. Mazzucchelli R, Corvasce S, Violin M, Riva C, Bianchi R, Deho L, et al. Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals. J Biol Regul Homeost Agents 2001;15:265-71.
72. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Levis I, Sodrosky J, et al. The lymphocyte chemoattractant SDF-1 is the ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33.
73. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-5.
74. Winkler C, Modi W, Smith M, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998;279:389-93.
75. Hendel H, Henon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, et al. Distinctive effect of CCR5, CCR2 and SDF1 genetic polymorphism in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:381-6.
76. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12:F85-90.
77. Brambilla A, Villa C, Rizardi G, Veglia F, Ghezzi S, Lazzarin A, et al. Shorter survival of SDF-1-3′A/3′A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type-1 infection. J Infect Dis 2000;182:311-5.
78. Balotta C, Bagnarelli P, Corvasce S, Mazzucchelli R, Colombo MC, Papagno L, et al. Identification of two distinct subsets of long term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. J Infect Dis 1999;180:285-9.
79. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multiceter AIDS Cohort Study. AIDS 2000;14:2671-8.
80. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999;96:4581-5.
81. Lusso P. HIV and chemokines: Implications for therapy and vaccine. Vaccine 2002;20:1964-7.
82. Trkola A, Paxton WA, Monard SP, Hoxie JA, Siani MA, Thompson DA, et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol 1998;72:396-404.
83. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999;73:684-94.
84. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibit recycling: A novel inhibitory mechanism of HIV infectivity. J Exp Med 1998;187:1215-24.
85. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel antagonist. Science 1997;276:276-9.
86. Arenzana-Seisdedos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B, et al. HIV blocked by chemokine antagonist. Nature 1996;383:400.
87. Ylisastigui L, Vizzavona J, Drakopoulou E, Paindavoine P, Calvo CF, Parmentier M, et al. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. AIDS 1998;12:977-84.
88. Proudfoot A, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, et al. Extention of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-603.
89. Kim D, Wang L, Hale JJ, Lynch CL, Budhu RJ, Maccoss, et al. Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: Effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg Med Chem Lett 2005;15:2129-34.
90. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, non peptide CCR5 antagonist with highly potent and selective anti HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703.
91. Este JA. Virus entry as a target for anti HIV intervention. Curr Med Chem 2003;10:1617-32.
92. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, et al. Novel low molecular weight spirodiketopeperazine derivative potently inhibit R5 HIV-1 inhibition through their antagonistic effect on CCR5. J Biol chem 2001;276:35194-200.
93. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, et al. Potent, broad spectrum inhibition of human immunodeficiency virus type-1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75:579-88.
94. Baroudy BM. Second generation CCR5 antagonist that inhibits HIV-1 entry. Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires: Argentina; 2001, Abstract 70.
95. Murakami T, Nakajima T, Koyanagi Y, Ttachibana K, Fujii N, Tamamura H, et al. A small molecule CXCR4 inhibitor that blocks T cell line tropic HIV-1 infection. J Exp Med 1997;186:1389-93.
96. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, et al. A small molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 co-receptor. J Exp Med 1997;186:1395-400.
97. Cabrera C, Gutierrez A, Barretina J, Blanco J, Litovchick A, Lapidot A, et al. Anti HIV activity of novel aminoglycoside-arginine conjugate. Antiviral Res 2002;53:1-8.
98. Cabrera C, Gutierrez A, Blanco J, Barrentina J, Litovchick A, Lapidot A, et al. Anti-human immunodeficiency virus activity of novel aminoglycoside- arginine conjugates at early stages of infection. AIDS Res Hum Retroviruses 2000;16:627-34.
99. Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4 mediated virus entry. Mol Pharmacol 2000;57:116-24.
100. Este JA, Cabrera C, de Clercq E, Struyf S, Van Damme J, Bridger G, et al. Activity of different bicyclam derivatives against human immuniodeficiency virus depends on their interaction with CXCR4 chemokine receptor. Mol Pharmacol 1999;55:67-73.
101. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-7.
102. Schols D, Este JA, Henson G, De Clercq E. Bicyclams, a class of potent anti HIV agents, are targeted at the HIV co-receptor fusin/CXCR4. Antiviral Res 1997;35:147-56.
103. de Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-7.
104. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH 1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-90.
105. Chen JD, Bai X, Yang AG, Cong Y, Chen SY. Inactivation of HIV-1 chemokine co-receptor CXCR4 by a novel intrakine strategy. Nat Med 1997;3:1110-6.
106. Martinez MA, Clotet B, Este JA. RNA interference of HIV replication. Trends Immunol 2002;23:559-61.
107. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002;16:2385-90.
108. Goila R, Banerjea AC. Sequence specific cleavage of HIV-1 co-receptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the coreceptor functions by DNA-enzymes. FEBS Lett 1998;436:233-8.
109. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, et al. Prevention of vaginal SHIV transmission in Rhesus macaques through inhibition of CCR5. Science 2004;306:485-7.
110. Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, et al. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 2004;78:7602-9.
111. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr, Kunstman K, et al. Use of a small molecule CCR5 inhibitor in macaques to treat Simian Immunodeficiency Virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003;198:1551-62.
112. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102.
113. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in hematopoiesis and in cerebellar development. Nature 1998;393:595-9.
114. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of gastrointestinal tract. Nature 1998;393:591-4.
115. Nagasawa T, Hirota S, Tachibana K, Takakura M, Nishikawa S, Kitamura Y, et al. Defects of B cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-8.
116. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004;78:11807-15.
117. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
118. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/co-receptor affinity, receptor density and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-54.